¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"toxic chemical regulation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chemical burn
    È­ÇÐÈ­»ó
  • chemical carcinogen
    È­Çй߾Ϲ°Áú
  • chemical carcinogenesis
    È­Çй߾Ï, È­ÇоÏÇü¼º
  • chemical cautery
    È­ÇÐÁöÁü¼ú
  • chemical coupling
    È­ÇÐÄ¿Çøµ
  • chemical defecation
    È­ÇÐÀûºÒ¼ø¹°Á¦°Å
  • chemical injury
    È­ÇÐÀû¼Õ»ó
  • chemical integration
    È­ÇÐÀûÅëÇÕ
  • chemical kinetics
    È­ÇйÝÀÀ¼Óµµ·Ð
  • chemical mediator
    È­ÇиŰ³Ã¼
  • chemical messenger
    È­ÇÐÀü·É, È­Çи޽ÅÀú
  • chemical mutagen
    È­ÇÐÀûµ¹¿¬º¯ÀÌÀ¯µµ¹°Áú
  • chemical oxygen demand
    È­ÇÐÀû»ê¼Ò¿ä±¸·®
  • chemical peel
    È­Çйþ±è¼ú, È­ÇйÚÇǼú
  • chemical peritonitis
    È­Çк¹¸·¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chemical shift artifact
    È­Çк¯À§Àΰø¹°
  • chemical burn
    È­ÇÐÈ­»ó
  • chemical
    È­ÇÐ-, È­Çй°Áú, È­Çоàǰ
  • chemical carcinogen
    È­Çй߾Ϲ°Áú
  • chemical carcinogenesis
    È­Çй߾ÏÇö»ó
  • chemical cautery
    È­ÇÐÁöÁü¼ú
  • chemical coupling
    È­ÇÐÄ¿Çøµ
  • chemical defecation
    È­ÇÐÀû¼øÈ­
  • chemical dosimeter
    È­Çм±·®°è
  • chemical injury
    È­ÇÐÀû¼Õ»ó
  • chemical integration
    È­ÇÐÀûÅëÇÕ
  • chemical kinetics
    È­ÇйÝÀÀ¼Óµµ·Ð
  • chemical mediator
    È­ÇиŰ³Ã¼
  • chemical messenger
    È­ÇÐÀûÀü·É
  • chemical mutagen
    È­ÇÐÀûµ¹¿¬º¯ÀÌÀ¯µµ¹°Áú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • paracrine regulation factor
    ÃøºÐºñ Á¶ÀýÀÎÀÚ
  • regulation
    ±ÔÁ¤
  • regulation of acid base equilibrium
    »ê-¿°±âÆòÇüÁ¶Àý(ß«ç¤ÐñøÁû¬ðàï½).
  • regulation of body temperature
    ü¿ÂÁ¶Àý(ô÷è®ðàï½).
  • regulation of gastric secretion
    À§»êºÐºñÁ¶Àý(êÖß«ÝÂù²ðàï½).
  • respiration regulation
    È£ÈíÁ¶Àý.
  • self regulation
    ÀÚ°¡Á¶Àý(í»Ê«ðàï½).
  • temperature regulation
    ü¿ÂÁ¶Àý(ô÷è® ðàï½).
  • agricultural chemical
    ³ó¾à.
  • chemical
    È­ÇÐ(Àû)ÀÇ
  • chemical
    È­ÇÐ(Àû)(ûùùÊîÜ)ÀÇ.
  • chemical
    È­ÇÐ(ûùùÊ)ÀÇ
  • chemical abortion
    È­ÇÐÀû À¯»ê
  • chemical affinity
    È­ÇÐģȭ·Â(¡­öÑûúæ³), È­ÇÐÀû ģȭ¼º.
  • chemical antagonism
    È­ÇÐÀû ±æÇ×ÀÛ¿ë
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chemical potential
    È­ÇÐ(ûùùÊ)Æ÷ÅÙ¼³
  • chemical quenching
    È­Çмұ¤(ûùùÊá¼ÎÃ)
  • chemical reaction
    È­ÇйÝÀÀ(ûùùÊÚãëë)
  • chemical score
    È­Çа¡(ûùùÊʤ)
  • chemical shift
    È­ÇÐÀû À̵¿(ûùùÊîÜì¹ÔÑ)
  • chemical synapse
    È­ÇÐ(ûùùÊ) ½Ã³³½º
  • chemical thermodynamics
    È­ÇÐ ¿­¿ªÇÐ(ûùùÊæðæ³ùÊ)
  • chemical transmitter
    È­ÇÐ Àü´Þ¹°(ûùùÊîîÓ¹Úª)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RTECS Registry of Toxic Effects of Chemical Substances
TRI tetrazolium reduction inhibition; Thyroid Research Institute; total response index; toxic chemical r...
TRIFACTS Toxic Chemical Release Inventory Facts
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
COD   1) Choice Of Drug
  2) Cause Of Death
  3) Chemical O2 Demand;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TEQ Toxic Equivalents
TOS Toxic Oil Syndrome
TRI Toxic Release Inventory
TSS Toxic Shock Syndrome
TSST-1 Toxic Shock Syndrome Toxin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • toxic action
    µ¶ ÀÛ¿ë
  • toxic amblyopia
    Áßµ¶ ¾à½Ã
  • toxic damage
    µ¶¼º ¼Õ»ó
  • toxic dyspepsia
    Áßµ¶¼º ¼ÒÈ­ ºÒ·®
  • toxic effect curve
    µ¶¼º °î¼±
  • toxic fume bronchiolitis obliterans
    µ¶¼º ¿¬±â¿¡ ÀÇÇÑ Æó¼â¼º ¼¼±â°üÁö¿°
    Áú¼Ò »êÈ­¹°, Æ÷½º°ÕÀ̳ª ±âŸ À¯µ¶ °¡½º¿¡ Æø·ÎµÈ ÈÄ 1-3ÁÖ ÈÄ ¹ß»ýÇÑ´Ù. ÈäºÎ ¹æ»ç¼± »çÁø»ó ¹Ì¸¸¼º ƯÀ̼º ÆóÆ÷ ¶Ç´Â °£À¯¸® À½¿µÀ» º¸ÀδÙ.
  • toxic mucosal damage
    µ¶¼º Á¡¸· ¼Õ»ó
  • toxic myocarditis
    Áßµ¶¼º ½É±Ù¿°
  • toxic reaction
    µ¶ ¹ÝÀÀ, Áßµ¶ ¹ÝÀÀ
  • toxic substance
    À¯µ¶ ¼ººÐ, µ¶¹°
  • toxic uninodular goiter
    Áßµ¶¼º ´Ü°áÀý¼º °©»ó¼±Á¾
  • chemical
    È­ÇÐÀÇ, È­ÇÐÀûÀÇ, È­ÇÐÀû
    1. È­ÇÐÀÇ ¶Ç´Â È­Çп¡ °üÇÑ. 2. È­ÇÐÀû ¿ä¼Ò·Î ±¸¼ºµÇ°Å³ª È­ÇÐ °úÁ¤¿¡ ÀÇÇØ ¾ò¾îÁø ¹°Áú.
  • chemical abrasion
    È­ÇÐÀû ¸¶¸ð
  • chemical affinity
    È­ÇРģȭ·Â, È­ÇÐÀû ģȭ¼º
  • chemical antagonism
    È­ÇÐÀû ±æÇ×ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
negative regulation Negative feedback in biological systems mediated by allosteric regulatory enzymes.
(18 Nov 1997)
down-regulation <physiology> Development of a refractory or tolerant state consequent upon repeated administration of a pharmacologically or physiologically active substance.
It is the process that decreases ligand and receptor interactions or reduces the responsiveness of a cell to a stimulus following first exposure.
This is often accompanied by an initial decrease in affinity of receptors for the agent and a subsequent reduction in the number of available receptors expressed on the surface which can result from internalisation of the ligand:receptor complex or from decreased expression of the receptor.
Classically the concept referred to hormone receptors but contemporary usage includes other cell surface receptors.
(03 Jul 1999)
target regulation <physiology> General term for an interaction between neurons and their targets by which target derived signals influence the differentiation of the innervating neurons.
(18 Nov 1997)
enzyme regulation <biochemistry> Control of the rate of a reaction catalyzed by an enzyme by some effector (e.g., inhibitors or activators) or by alteration of some condition (e.g., pH or ionic strength).
(05 Mar 2000)
facility regulation and control Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer.
(12 Dec 1998)
feedback regulation <physiology> Control mechanism that uses the consequences of a process to regulate the rate at which the process occurs: if, for example: the products of a reaction inhibit the reaction from proceeding (or slow down the rate of the reaction), then there is negative feedback, something that is very common in metabolic pathways.
Positive feedback is liable to lead to exponential increase and may be explosively dangerous in some cases.
Other examples are the action of voltage dependent sodium channels in generating action potentials and the activation of blood clotting factors V and VIII by thrombin. Without damping, feedback can lead to resonance (hunting) and oscillation in the system.
(18 Nov 1997)
up-regulation Opposite of down-regulation.
(05 Mar 2000)
up-regulation (physiology) Process that increases ligand/receptor interactions due to an increase in the number of available receptors.
(12 Dec 1998)
megacolon, toxic Acute dilatation of the colon associated with amebic or ulcerative colitis. The dilatation may precede perforation of the colon.
(12 Dec 1998)
goiter, diffuse toxic Graves' disease, the most common cause of hyperthroidism, too much thyroid hormone.
(12 Dec 1998)
goiter, toxic multinodular Condition in which the thyroid gland contains multiple lumps (nodules) that are overactive and produce excess thyroid hormones. This condition is also known as Parry's disease or Plummer's disease.
(12 Dec 1998)
plants, toxic Plants or plant parts which are harmful to man or other animals.
(12 Dec 1998)
hepatitis, toxic Acute hepatitis caused by true hepatotoxins such as amanita phaloides toxin, carbon tetrachloride, yellow phosphorus, and a variety of drugs.
(12 Dec 1998)
shock, toxic See Syndrome, toxic shock.
(12 Dec 1998)
syndrome, toxic shock A grave condition occurring predominantly in menstruating women using tampons, toxic shock is characterised by a highly toxic state (with sudden high fever, vomiting, diarrhoea, muscle aching) followed by low blood pressure (hypotension) which can lead to shock (and death). There may be a rash resembling sunburn with peeling of skin. The channing laboratory in boston under dr. Edw. Kass discovered that toxic shock was due to a toxin produced by staph (staphylococcus) aureus bacteria growing under conditions with little or no oxygen. The syndrome occurs rarely in women not using tampons and in men.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á